KSHV vIL-6 Enhances Inflammatory Responses by Epigenetic Reprogramming

Kaposi sarcoma-associated herpesvirus (KSHV) inflammatory cytokine syndrome (KICS) is a newly described chronic inflammatory disease condition caused by KSHV infection and is characterized by high KSHV viral load and sustained elevations of serum KSHV-encoded IL-6 (vIL-6) and human IL-6 (hIL-6). KICS has significant immortality and possesses greater risks of having other complications, which include malignancies. Although prolonged inflammatory vIL-6 exposure by persistent KSHV infection is expected to have key roles in subsequent disease development, the biological effects of prolonged vIL-6 exposure remain elusive. Using thiol-Linked Alkylation for the Metabolic Sequencing and Cleavage Under Target & Release Using Nuclease analysis, we studied the effect of prolonged vIL-6 exposure in chromatin landscape and resulting cytokine production. The studies showed that prolonged vIL-6 exposure increased Bromodomain containing 4 (BRD4) and histone H3 lysine 27 acetylation co-occupancies on chromatin, and the recruitment sites were frequently co-localized with poised RNAPII with associated enzymes. Increased BRD4 recruitment on promoters was associated with increased and prolonged NF-KB p65 binding after the lipopolysaccharide stimulation. The p65 binding resulted in quicker and sustained transcription bursts from the promoters; this mechanism increased total amounts of hIL-6 and IL-10 in tissue culture. Pretreatment with the BRD4 inhibitor, OTX015, eliminated the enhanced inflammatory cytokine production. These findings suggest that persistent vIL-6 exposure may establish a chromatin landscape favorable for the reactivation of inflammatory responses in monocytes. This epigenetic memory may explain the greater risk of chronic inflammatory disease development in KSHV-infected individuals. Author summary Combined and continuous cytokine stimulation triggers transcription reprogramming and is often used for specific tissue development. Continuous vIL-6 exposure occurs in KSHV-infected patients and leads to inflammatory cytokine storm with high mortality. However, possible epigenetic reprogramming by the vIL-6 and its association with pathogenesis remain unclear. Here we demonstrate the establishment of a new chromatin landscape mediated by BRD4 through prolonged vIL-6 exposure which contributes to more robust and rapid transcription and increased cytokines production. Inhibition of BRD4 suppressed this inflammatory response. Our results indicate that targeting the epigenetic effect of viral cytokines may lead to novel therapies for KSHV-induced inflammatory cytokine storms.

[1]  C. Tepper,et al.  KSHV uses viral IL6 to expand infected immunosuppressive macrophages , 2023, bioRxiv.

[2]  Frank Y. S. Chuang,et al.  KSHV episome tethering sites on host chromosomes and regulation of latency-lytic switch by CHD4 , 2022, Cell reports.

[3]  Shinya Oki,et al.  ChIP-Atlas 2021 update: a data-mining suite for exploring epigenomic landscapes by fully integrating ChIP-seq, ATAC-seq and Bisulfite-seq data , 2022, Nucleic Acids Res..

[4]  Brad T. Sherman,et al.  DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update) , 2022, Nucleic Acids Res..

[5]  T. Hirano IL-6 in inflammation, autoimmunity and cancer , 2020, International immunology.

[6]  G. Soma,et al.  A unique hybrid characteristic having both pro- and anti-inflammatory phenotype transformed by repetitive low-dose lipopolysaccharide in C8-B4 microglia , 2020, Scientific Reports.

[7]  Shou-Jiang Gao,et al.  Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1 , 2020, Oncogene.

[8]  Binqing Fu,et al.  Why tocilizumab could be an effective treatment for severe COVID-19? , 2020, Journal of Translational Medicine.

[9]  Ming-Ming Zhou,et al.  Roles of the BRD4 short isoform in phase separation and active gene transcription , 2020, Nature Structural & Molecular Biology.

[10]  Huan Gao,et al.  BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling , 2020, Oncogenesis.

[11]  Veronika A. Herzog,et al.  Quantification of experimentally induced nucleotide conversions in high-throughput sequencing datasets , 2019, BMC Bioinform..

[12]  B. Berges,et al.  The Kaposi's sarcoma-associated herpesvirus viral interleukin 6 gene affects metastasis and expression of B cell markers in a murine xenograft model , 2018, PloS one.

[13]  Krishna Sundar Twayana,et al.  Prolonged lipopolysaccharide exposure induces transient immunosuppression in BV2 microglia , 2018, Journal of cellular physiology.

[14]  Daniel S. Day,et al.  Coactivator condensation at super-enhancers links phase separation and gene control , 2018, Science.

[15]  Jia Gu,et al.  fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.

[16]  Johannes Zuber,et al.  Thiol-linked alkylation of RNA to assess expression dynamics , 2017, Nature Methods.

[17]  Rob Patro,et al.  Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.

[18]  Vivien A. C. Schoonenberg,et al.  β-Glucan Reverses the Epigenetic State of LPS-Induced Immunological Tolerance , 2016, Cell.

[19]  M. Robinson,et al.  Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences , 2015, F1000Research.

[20]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[21]  David C. Norris,et al.  Integrated genome browser: visual analytics platform for genomics , 2015, bioRxiv.

[22]  S. Goerdt,et al.  Macrophage activation in human diseases. , 2015, Seminars in immunology.

[23]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[24]  D. Reinberg,et al.  BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones , 2014, Nature Structural &Molecular Biology.

[25]  R. Xavier,et al.  Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity , 2014, Science.

[26]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[27]  Y. Guo,et al.  Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway , 2014, Oncogene.

[28]  Arndt von Haeseler,et al.  NextGenMap: fast and accurate read mapping in highly polymorphic genomes , 2013, Bioinform..

[29]  H. Kung,et al.  Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Latency-Associated Nuclear Antigen Regulates the KSHV Epigenome by Association with the Histone Demethylase KDM3A , 2013, Journal of Virology.

[30]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[31]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[32]  E. Pamer,et al.  Monocyte recruitment during infection and inflammation , 2011, Nature Reviews Immunology.

[33]  Martin Lundberg,et al.  Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood , 2011, Nucleic acids research.

[34]  D. Ganem,et al.  Array-Based Transcript Profiling and Limiting-Dilution Reverse Transcription-PCR Analysis Identify Additional Latent Genes in Kaposi's Sarcoma-Associated Herpesvirus , 2010, Journal of Virology.

[35]  G. Sandford,et al.  Determinants of Secretion and Intracellular Localization of Human Herpesvirus 8 Interleukin-6 , 2009, Journal of Virology.

[36]  G. Sandford,et al.  Intracellular Signaling Mechanisms and Activities of Human Herpesvirus 8 Interleukin-6 , 2008, Journal of Virology.

[37]  J. Nicholas,et al.  Signal Transduction by Human Herpesvirus 8 Viral Interleukin-6 (vIL-6) IsModulated by the Nonsignaling gp80 Subunit of the IL-6 Receptor Complex and Is Distinct from Signaling Induced by Human IL-6 , 2006, Journal of Virology.

[38]  A. Kalita,et al.  JAK/STAT3 Pathway Is Involved in Survival of Neurons in Response to Insulin-like Growth Factor and Negatively Regulated by Suppressor of Cytokine Signaling-3* , 2005, Journal of Biological Chemistry.

[39]  Eric B Haura,et al.  Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.

[40]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[41]  K. Garcia,et al.  Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. , 2004, Journal of molecular biology.

[42]  A. Nicolini,et al.  Prolonged exposure of microglia to lipopolysaccharide modifies the intracellular signaling pathways and selectively promotes prostaglandin E2 synthesis , 2003, Journal of neurochemistry.

[43]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[44]  P. Galle,et al.  IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-61 , 2000, The Journal of Immunology.

[45]  Y. Chang,et al.  KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. , 1999, Human immunology.

[46]  E. Jaffe,et al.  Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. , 1999, Blood.

[47]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[48]  M. Corbellino,et al.  Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. , 1997, The American journal of pathology.

[49]  C. Boshoff,et al.  Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV , 1996, Science.

[50]  A. Dalgleish,et al.  Kaposi's sarcoma. , 1991, British Journal of Cancer.

[51]  B. Damania,et al.  KSHV: pathways to tumorigenesis and persistent infection. , 2014, Advances in virus research.

[52]  M. Meads,et al.  Kaposi’s Sarcoma-associated Herpesvirus-encoded Viral Interleukin-6 Is Secreted and Modified Differently Than Human Interleukin-6 EVIDENCE FOR A UNIQUE AUTOCRINE SIGNALING MECHANISM* , 2004 .

[53]  K. Garcia,et al.  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. , 2003, Science.